Wire · opportunities
FDA Approves First-in-Class Centanafadine for Treatment of ADHD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
FDA approved centanafadine (Simtriyo), the first NDSRI CNS stimulant for ADHD in patients aged 6+ years, following phase 3 trials showing statistically significant symptom improvement with effects emerging by week 1. The drug carries boxed warnings for suicidal ideation in children and abuse/addiction potential, with commercial availability expected after DEA scheduling.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
If you're building ADHD diagnostic tools, patient monitoring software, or clinical decision support for psychiatrists, a new drug class has just entered the market with mandatory close monitoring requirements for suicidality and abuse risk. That compliance and safety infrastructure is now table stakes.
◆ Coverage
1 source · 27 Jul 2026
◆ Related on Wire
◆ Topics